X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Azol
2. Cyclomen
3. Danatrol
4. Danazant
5. Danazol Ratiopharm
6. Danazol-ratiopharm
7. Danocrine
8. Danol
9. Danoval
10. Ladogal
11. Norciden
12. Panacrine
1. Danocrine
2. 17230-88-5
3. Chronogyn
4. Winobanin
5. Danol
6. Cyclomen
7. Danazolum
8. Ladogal
9. Danzol
10. Danatrol
11. Danazol, Usp
12. Win-17757
13. Win 17,757
14. Danazole
15. N29qww3buo
16. (1r,3as,3br,10ar,10bs,12as)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
17. Win 17757
18. Danovaol
19. Chebi:4315
20. Danokrin
21. Nsc-270916
22. Ncgc00164400-01
23. Danogen
24. Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)-
25. Dsstox_cid_2880
26. Danazolum [inn-latin]
27. Nsc 270916
28. Dsstox_rid_76772
29. Dsstox_gsid_22880
30. Bonzol
31. Danocrine (tn)
32. Smr000058321
33. Ccris 6747
34. Einecs 241-270-1
35. Unii-n29qww3buo
36. Vasaloc
37. 17-alpha-pregn-4-en-20-yno(2,3-d)isoxazol-17-ol
38. Optina
39. Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17alpha)-
40. 17-alpha-2,4-pregnadien-20-yno(2,3-d)isoxazol-17-ol
41. 17alpha-pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol
42. Nsc270916
43. Win 17, 757
44. Prestwick_150
45. Cas-17230-88-5
46. Danazol [usan:usp:inn:ban:jan]
47. Danazol [vandf]
48. Ethynyl(dimethyl)[?]ol
49. 2,3-isoxazolethisterone
50. Danazol [usan]
51. Danazol [inn]
52. Danazol [jan]
53. Danazol [mi]
54. Danazol [mart.]
55. Prestwick0_000105
56. Prestwick1_000105
57. Prestwick2_000105
58. Prestwick3_000105
59. Danazol [usp-rs]
60. Danazol [who-dd]
61. Chembl1479
62. Schembl21107
63. Bspbio_000090
64. (1s,2r,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol
65. Mls001066617
66. Mls001306473
67. Danazol (jp17/usp/inn)
68. Danazol [orange Book]
69. Spbio_002029
70. Bpbio1_000100
71. Gtpl6942
72. Danazol [usp Monograph]
73. Dtxsid2022880
74. 2,4,17alpha-pregnadien-20-yno[2,3-d]-isoxa-zol-17-ol
75. Win-17,757
76. Hms1568e12
77. Hms2090a22
78. Hms2095e12
79. Hms2231m08
80. Hms3259m10
81. Hms3712e12
82. Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17alpha)-
83. [1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol
84. 17.alpha.-pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol}
85. Bcp11914
86. Hy-b1029
87. Zinc3881958
88. Tox21_112114
89. Tox21_301940
90. Bdbm50423541
91. Mfcd00056838
92. S9506
93. Akos015961192
94. Tox21_112114_1
95. Ac-6836
96. Ccg-220105
97. Cs-4547
98. Danazol 100 Microg/ml In Acetonitrile
99. Db01406
100. Nc00557
101. Ncgc00179665-01
102. Ncgc00179665-02
103. Ncgc00179665-04
104. Ncgc00255335-01
105. (1r,3as,3br,10ar,10bs,12as)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol
106. 1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
107. As-13035
108. C06938
109. D00289
110. 230d885
111. Q419652
112. Sr-01000760722
113. Sr-05000000445
114. Sr-01000760722-2
115. Sr-05000000445-2
116. W-107864
117. 17a-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol
118. Brd-k48970916-001-03-0
119. (17a)-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol
120. 17a-pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17b-ol
121. 1-(p-tosyl)-3,4,4-trimethyl-2-imidazoliniumiodide
122. 17 Alpha-pregna-2,4-dien-20-yno[2,3-d] Isoxazol-17 Beta-ol
123. 17.alpha.-pregna-2,4-dien-20-yno(2,3)-disoxazol-17-ol
124. Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol,} (17.alpha.)-
125. Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17.alpha.)-
126. (1s,2r,13r,14s,17r,18s)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol
127. 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol
128. 1h-cyclopenta[7,8]phenanthro[3,2-d]isoxazole- Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol Deriv.
| Molecular Weight | 337.5 g/mol |
|---|---|
| Molecular Formula | C22H27NO2 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 337.204179104 g/mol |
| Monoisotopic Mass | 337.204179104 g/mol |
| Topological Polar Surface Area | 46.3 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 677 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Danazol |
| PubMed Health | Danazol (By mouth) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Danazol is a synthetic steroid derived from ethisterone. It is a white to pale yellow crystalline powder, practically insoluble or insoluble in water, and sparingly soluble in alcohol. Chemically, danazol is 17-Pregna-2, 4-dien-20-yno [2, 3- ]-isox... |
| Active Ingredient | Danazol |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 200mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Lannett; Barr |
| 2 of 2 | |
|---|---|
| Drug Name | Danazol |
| PubMed Health | Danazol (By mouth) |
| Drug Classes | Endocrine-Metabolic Agent |
| Drug Label | Danazol is a synthetic steroid derived from ethisterone. It is a white to pale yellow crystalline powder, practically insoluble or insoluble in water, and sparingly soluble in alcohol. Chemically, danazol is 17-Pregna-2, 4-dien-20-yno [2, 3- ]-isox... |
| Active Ingredient | Danazol |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 200mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Lannett; Barr |
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-releasing hormone (GnRH) agonists. Danazol has antigonadotropic and anti-estrogenic activities. Danazol acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties.
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03X - Other sex hormones and modulators of the genital system
G03XA - Antigonadotropins and similar agents
G03XA01 - Danazol
Hepatic, to principal metabolites, ethisterone and 17-hydroxymethylethisterone.
Approximately 24 hours.
As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby reducing ovarian estrogen production. Danazol may also directly inhibits ovarian steroidogenesis; bind to androgen, progesterone, and glucocorticoid receptors; bind to sex-hormone-binding globulin and corticosteroid-binding globulin; and increases the metabolic clearance rate of progesterone. Another mechanism of action by which danazol may use to facilitate regression of endometriosis is by decreasing IgG, IgM, and IgA concentrations, as well as phospholipid and IgG isotope autoantibodies. In the treatment of endometriosis, as a consequence of suppression of ovarian function, danazol causes both normal and ectopic endometrial tissues to become inactive and atrophic. This leads to anovulation and associated amenorrhea. In fibrocystic breast disease, the exact mechanism of action of danazol is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue is also possible. This leads to a disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern. In terms of hereditary angioedema, danazol corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB)
Market Place
